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Fibroblasts are widely distributed cells and are responsible for the deposition of extracellular matrix (ECM) components but also
secrete ECM-degrading matrix metalloproteases. A ﬁnely balanced equilibrium between deposition and degradation of ECM is
essential for structural integrity of tissues. In the past, ﬁbroblasts have typically been understood as a uniform cell population
with comparable functions regardless of their origin. Here, we determined growth curves of ﬁbroblasts derived from heart, skin,
and lung and clearly show the lowest proliferation rate for cardiac ﬁbroblasts. Furthermore, we examined basal expression levels of
collagenanddiﬀerentMMPsinthesethreetypesofﬁbroblastsandcomparedtheseconcerningtheirsiteoforigin.Interestingly,we
found major diﬀerences in basal mRNA expression especially for MMP1 and MMP3. Moreover, we treated ﬁbroblasts with TNF-α
and observed diﬀerent alterations under these proinﬂammatory conditions. In conclusion, ﬁbroblasts show diﬀerent properties in
proliferation and MMP expression regarding their originated tissue.
1.Introduction
Fibroblasts are a heterogeneous population of cells found in
numerous tissues and are of mesenchymal origin. The most
common products secreted by ﬁbroblasts are components
of the extracellular matrix (ECM) such as diﬀerent types
of collagen, ﬁbronectin, and proteoglycans [1–5]. The ECM
preserves the geometry and structural integrity of various
organs and tissues, but it is not only a scaﬀold that
provides support for cells, but is further involved in cell-
cell interactions, proliferation, and migration. The dermis is
composed of the predominating ECM and the fewer cellular
constituents of mainly ﬁbroblasts which provides ﬂexibility
and physical strength to skin [6]. In the heart ﬁbroblasts
are 70% of the cells in the myocardium, whereas myocytes
occupy two-thirds of the tissue volume [7–9]. Pulmonary
ﬁbroblasts are also present in the connective tissue of the
airway wall under the surface epithelium [10].
Moreover, ﬁbroblasts are not only involved in the
depositionofECMproductsbutalsosecreteECM-degrading
enzymes called matrix metalloproteases (MMPs) and there-
fore are involved in the degradation of ECM. These MMPs
are zinc-dependent endopeptidases secreted by ﬁbroblasts
and functioning extracellularly [2, 4, 5, 11]. Their substrates
are marcomolecules of the ECM network consisting of
diﬀerent collagen types, proteoglycans, and glycoproteins.
They are classiﬁed as collagenases, gelatinases, stromelysins,
and membrane-type MMPs according to their substrate
speciﬁcity. Collagenases cleave collagens at unique sites
generating 75–25kDa fragments called gelatins which were
further degraded into single amino acids or oligopeptids by
the gelatinases [12].
Inthisstudyweisolatedthreetypesofhumanﬁbroblasts,
namely, cardiac, dermal, and pulmonary ﬁbroblasts. We
investigated the proliferation of ﬁbroblasts in accordance to
their diﬀerent tissue origins to determine whether tissue-
speciﬁc proliferation rates of this cell type can be found.
Furthermore, ﬁbroblasts play a key role in normal matrix
turnover as well as in pathological matrix deposition or
degradation which can occur, for instance, during ﬁbrosis2 Biochemistry Research International
or inﬂammation. We hypothesized tissue-speciﬁc expression
levels of MMPs in the diﬀerent types of ﬁbroblasts. There-
fore, we determined the basal MMP expression of primary
human ﬁbroblasts derived from heart, lung, and skin.
Thereby we focused on these MMPs which are described to
be expressed in cardiac tissue [2].
TNF-α is a proinﬂammatory cytokine, which plays a key
role in myocardial inﬂammatory response after myocardial
infarction [13]. In the early stage, the predominant sources
of TNF-α are the inﬁltrated inﬂammatory cells. In this study
we demonstrate diﬀerent MMP expression of ﬁbroblasts
according to their site of origin in response to TNF-α.
2.MaterialsandMethods
2.1. Isolation and Culture of Human Cardiac, Dermal, and
Pulmonary Fibroblasts. Human cardiac, dermal, and pulmo-
nary ﬁbroblasts were obtained by outgrowth from biopsies
from four, three, or two patients, respectively. The endomy-
ocardial biopsies were obtained from the right side of the
ventricular septum of patients with dilated cardiomyopathy
(ejection fraction < 30). Used was a ﬂexible bioptome via
the femoral vein approach. For dermal ﬁbroblasts skin tissue
which remained after surgery was used. The lung biopsies
were obtained by bronchoscopy.
PrimaryhumanﬁbroblastswereculturedinIscove’sbasal
medium (Biochrom AG, Berlin, Germany) containing 10%
human serum, 10% fetal calf serum, 100U/mL penicillin,
and100μg/mLstreptomycin(PAA,C¨ olbe,Germany)at37◦C
in a humidiﬁed atmosphere with 5% CO2 and 95% air. All
further experiments were done with cells between the second
and the fourth passage.
2.2. Immunoﬂuorescence Staining of Primary Human Fibrob-
lasts. Cells to be characterized were seeded out into 48-
well plates and grown to approximately 80% conﬂuence.
Cells were then ﬁxed in 4% paraformaldehyde at room
temperature for 10 minutes. Subsequently, cells were per-
meabilized with 0.25% Triton X-100 in TBS for 10 minutes
followed by blocking with TBS containing 0.25% Triton
X-100 and 1.5% normal rabbit serum for vimentin and
desmin staining or 1.5% normal horse serum for CD31
and P4HB staining for 30 minutes at room temperature
using the sera of Vectastain Elite ABC Kit and the avidin
solution (Vector Laboratories, Burlingame, CA). Cells were
exposed to a goat anti-vimentin antibody (Sc-7558, Santa
Cruz, Heidelberg, Germany) or a goat anti-desmin antibody
(Sc-7559, Santa Cruz, Heidelberg, Germany) in the presence
of the biotin solution (Vector Laboratories, Burlingame, CA)
for 90 minutes followed by 60-minute incubation with a
biotinylated secondary anti-goat antibody raised in rabbit.
For CD31 and P4HB visualization cells were incubated with
an mouse anti-CD31 antibody (M0823, Dako, Hamburg,
Germany) or a mouse anti-P4HB antibody (H00005034-
B01P, Abnova, Heidelberg, Germany) in the presence of
the biotin solution (Vector Laboratories, Burlingame, CA)
for 90 minutes followed by incubation with a biotinylated
secondary anti-mouse antibody raised in horse for 60
minutes. For ﬂuorescence visualization cells were ﬁnally
incubated with 9μg/mL Cy3-conjugated streptavidin (016-
160-084, Jackson ImmunoResearch, Suﬀolk, UK) diluted
in TBS containing 0.25% Triton X-100 for 30 minutes
followed by a nuclear staining with Dapi (D1168, Invitrogen,
Darmstadt, Germany) for 10 minutes. Cells were covered
with TBS and analysed by ﬂuorescence microscopy.
2.3. Proliferation of Primary Human Fibroblasts. To deter-
mine the doubling time of ﬁbroblasts they were seeded
out into 96-well plates and allowed to attach for 48 hours.
Every second or third day only three wells of the 96-well
plates were incubated with CellTiter-Blue viability solution
(Promega, Mannheim, Germany) diluted in complete cell
culture medium as recommended and incubated at 37◦Ci n
a humidiﬁed atmosphere with 5% CO2 and 95% air for 2
hours. The colour development was monitored at 560nm
with a reference wave length of 620nm. Growth curves were
plotted as x-fold of reference corrected optical density (OD)
compared to the ﬁrst measurement 48 hours after seeding.
The doubling time was calculated using following formula,
DT = [t −t0]log2/[logN −logN0], where N and N0 are the
detected OD560–620 at times t and t0,r e s p e c t i v e l y .
2.4. Stimulation of Human Fibroblasts. For stimulation
experiments the primary human ﬁbroblasts were seeded
out into 24-well plates. When the culture was about 80%
conﬂuence, cells were washed once and serum-starved in
Iscove’s basal medium (Biochrom AG, Berlin, Germany)
containing 0.5% FCS, 100 U/mL penicillin, and 100μg/mL
streptomycin (PAA, C¨ olbe, Germany) 16 hours prior to the
experiment. Cells were then treated with a ﬁnal concentra-
tion of 10ng/mL TNF-α ( P e p r o t e c h ,H a m b u r g ,G e r m a n y )
in the serum-starved medium and incubated at 37◦Ci na
humidiﬁed atmosphere with 5% CO2 and 95% air for 24
hours. As unstimulated control cells were treated equally
without addition of TNF-α and incubated for the same
time period. At the end of the experiment cell culture
supernatants were collected and stored at −80◦C. Cells were
washed once with PBS and lysed immediately in RLT-Buﬀer
(Qiagen, Hilden, Germany) containing 1% mercaptoethanol
and stored at −80◦C until total RNA isolation. Stimulation
experiments were carried out with n = 6 wells per
experiment for all patients and repeated at least twice for
each patient.
2.5. RNA Isolation, cDNA Transcription, and Real-Time
PCR. Total RNA was isolated from cells using RNeasy kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. Brieﬂy, after cell lysis with RLT-Buﬀer
containing 1% mercaptoethanol equal volume of 70%
ethanol was added and transferred to the RNeasy columns.
Columns were washed once with RW1-Buﬀer and DNA was
digested directly at the column using RNase free DNase I
(Qiagen, Hilden, Germany) for 15 minutes to avoid genomic
DNA contamination. Subsequently, columns were washed
again with RW1-Buﬀer followed by two washing steps
with RPE-Buﬀer. Finally, the total RNA was eluted usingBiochemistry Research International 3
P
4
H
B
C
D
3
1
D
e
s
m
i
n
V
i
m
e
n
t
i
n
Cardiac ﬁbroblasts Dermal ﬁbroblasts Pulmonary ﬁbroblasts HL1 cells HMEC-1 cells
Figure 1: Characterization of primary human ﬁbroblasts. Cells were obtained by outgrowth form tissue samples from heart, skin, and lung.
They were stained with antibody directed against vimentin, desmin, CD31, and P4HB. They show positive staining for vimentin and P4HB
and were therefore characterized as ﬁbroblasts.
water. The yield of puriﬁed total RNA was determined by
measuring the UV absorbance at 260nm on the Nanodrop
ND1000 spectrophotometer. cDNA was obtained from
250ng total RNA using the high-capacity kit (Applied
Biosystems) according to the manufacturer’s protocol and
ﬁnally diluted to a concentration of 1.25ng/μL for further
analysis. To assess the mRNA expression of the target
genes real-time PCR was performed using 5μL of the gene
expression master mix (Applied Biosystems) and the 0.5μL
of the gene expression assay for Col1A1 (Hs00164004 m1),
MMP1 (Hs00233958 m1), MMP2 (Hs00234422 m1),
MMP3 (Hs00968305 m1), MMP7 (Hs01042795 m1),
MMP8 (Hs00233972 m1), MMP9 (Hs00234579 m1),
MMP13 (Hs00122992 m1), and MMP14 (Hs00237119 m1)
(each includes forward and reverse primers as well the
ﬂuorescently FAM-labelled probe) from Applied Biosystems
and 1μLo fc D N Ai naﬁ n a lv o l u m eo f1 0μL. Quantiﬁcation
of the house-keeping gene CDKN1b (Hs00153277 m1) as
an internal control was performed for each sample. All data
were normalized to CDKN1b mRNA level as an endogenous
control (unaﬀected by TNF-α treatment). In ﬁgures as
well as in Table 1 the data are expressed as absolute mRNA
expression levels using the formula 2−ΔCt. To highlight the
diﬀerent response to external stimuli the data in Table 2
are expressed as relative mRNA expression levels using the
formula 2−ΔΔCt.
2.6. Zymography. The gelatinolytic activity of the cell culture
supernatant was determined by gelatine zymography. The
samples were mixed with 5x sample buﬀe ra n dl o a d e do n
a 10% sodium dodecylsulfate-polyacrylamide electrophore-
sis gel copolymerized with 1mg/mL gelatine. After elec-
trophoresis the gel was incubated in 2.5% Triton X-100 for
60 minutes. The gel was then incubated in 0.05M TrisHCl,
0.2M NaCl, 7mM CaCl2,5 0m MM g C l 2, and 0.2% Brji at
37◦C over night. The gel was stained with 0.5% coomassie
blue G250 for 3 hours. After destaining the MMP9 activity
was detected as clear bands against the blue background. The
area of the clear bands was determined using ImageJ and
expressed as x-fold over untreated control.
2.7. Statistical Analysis. Data are shown as mean ± SEM.
For comparison the nonparametric Mann-Whitney U test
was used. Diﬀerences were considered signiﬁcant when the
probability value P is lower than 0.05. All analyses were
performed using Graph Pad Prism 5.0 software (GraphPad
Software, La Jolla, CA).
3. Results
3.1. Characterization of Human Fibroblasts. To positively
identify the cells populating our primary cultures as ﬁbrob-
lasts, the cells obtained by the outgrowth from biopsies
were stained with diﬀerent markers (Figure 1). Cardiac,
dermal, and pulmonary presumable ﬁbroblasts as well as
the cardiomyocyte cell line HL1 and the endothelial cell line
HMEC-1 expressed the cytosolic localized structural protein
vimentin. Furthermore, the primary cells did not express
the muscle marker desmin and the endothelial cell surface
marker CD31 in contrast to the HL1 and the HMEC-14 Biochemistry Research International
Table 1: Absolute mRNA expression levels of diﬀerent MMPs in cardiac, dermal, and pulmonary human ﬁbroblasts. The mRNA expression
was normalized to the housekeeping gene CDKN1b using the formula 2−ΔCt. For statistical signiﬁcance dermal or pulmonary expression was
compared to the expression in cardiac ﬁbroblasts using Mann-Whitney U test.
Absolute mRNA expression level
(normalized to CDKN1b)
Gene Cardiac ﬁbroblast Dermal ﬁbroblast Pulmonary ﬁbroblast
Expression Expression x-fold to cardiac
ﬁbroblast P value Expression x-fold to cardiac
ﬁbroblast P value
MMP1 12 ±30 .49 ±0.08 −24 <0.0001 0.67 ±0.12 −17 <0.0001
MMP2 104 ±10 111 ±6 1.1 0.559 88 ±8 −1.2 0.411
MMP3 0.29 ±0.08 2.1 ±0.3 7.0 <0.0001 0.033 ±0.007 −8.9 0.155
MMP7 0.005 ±0.001 0.0024±0.0006 −2.0 0.013 0.0005±0.0001 −9.2 <0.0001
MMP8 0.040 ±0.013 0.0006±0.0002 −63 <0.0001 0.0007±0.0002 −54 <0.0001
MMP9 0.010 ±0.003 0.028 ±0.005 2.7 0.003 0.0055±0.0012 −1.9 0.292
MMP14 41 ±51 5 ±1 −2.8 <0.0001 26 ±2 −1.6 0.033
Table 2: Relative mRNA expression level of diﬀerent MMPs in cardiac, dermal, and pulmonary human ﬁbroblasts after treatment with
10ng/mL TNF-α for 24 hours. The mRNA expression was normalized to the housekeeping gene CDKN1b and to the according untreated
control using the formula 2−ΔΔCt and is given as x-fold increase. For statistical signiﬁcance treated and untreated control were compared
using Mann-Whitney U test.
relative mRNA expression level after TNF-α stimulation for 24 hours
(normalized to unstimulated control)
Gene Cardiac ﬁbroblast Dermal ﬁbroblast Pulmonary ﬁbroblast
expression P value expression P value expression P value
(x-fold to control) (x-fold to control) (x-fold to control)
MMP1 2.0 ±0.2 0.044 100 ±12 <0.0001 6.0 ±0.8 <0.0001
MMP2 1.6 ±0.1 0.0002 1.2 ±0.1 0.023 1.2 ±0.0 0.007
MMP3 6.7 ±1.2 <0.0001 9.8 ±1.8 <0.0001 16 ±3 <0.0001
MMP7 16 ±4 <0.0001 3.3 ±0.3 <0.0001 3.1 ±0.5 0.0006
MMP8 5.7 ±1.2 <0.0001 130 ±50 <0.0001 10 ±2 <0.0001
MMP9 7.5 ±2.4 0.005 127 ±27 <0.0001 90 ±11 <0.0001
MMP14 1.6 ±0.1 0.018 1.6 ±0.3 0.103 1.2 ±0.1 0.317
cells, respectively. However, the primary cells did exhibit a
strongly detectable signal for prolyl 4-hydroxylase (P4HB).
This enzyme is essential for the synthesis of collagen, one of
the most prominent products of ﬁbroblasts. Consequently,
theses cultures contained almost exclusively primary cardiac,
dermal, or pulmonary ﬁbroblasts.
3.2. Proliferation. To determine the diﬀerent growth rate of
primary human ﬁbroblasts with diﬀerent origins, cardiac,
dermal, and pulmonary ﬁbroblasts were seeded out into 96-
w e l lp l a t e sa n dc u l t u r e di nc o m p l e t eg r o w t hm e d i u mf o r
14 days. After diﬀerent time periods cells were incubated
with cellTiter viability assay and the colour development
was monitored. The ﬁrst measurement was done 48 hours
after seeding out. Growth curves of cardiac, dermal, and
pulmonary ﬁbroblasts in complete growth medium are
presented in Figure 2(a). It is clearly shown that cardiac
ﬁbroblasts proliferate much slower compared to ﬁbroblasts
derived from skin or lung. The calculated doubling time of
cardiac ﬁbroblasts was with 12.2 days approximately 4-fold
longer compared to the doubling time of 3.7 and 3.3 days of
the dermal and pulmonary ﬁbroblasts, respectively.
3.3. Basal Expression of Collagen and Matrix Metalloproteases
in Cardiac, Dermal, and Pulmonary Fibroblasts. To inves-
tigate the basal expression levels of ﬁbroblasts according
to their site of origin the mRNA expression level of the
untreated control cells after incubation in serum-starved
medium for approximately 16 and additional 24 hours was
determined using real-time PCR analysis. Therefore, total
RNA was extracted from cells and transcribed into cDNA
followed by TaqMan for quantiﬁcation. The determined
mRNA expression levels for Col1A1 and MMPs are shown
in Figures 2(b) and 2(c),r e s p e c t i v e l y .
A similar collagen 1A1 expression level was found in
cardiac and pulmonary ﬁbroblasts. Interestingly an ap-
proximately 2-fold higher expression of collagen 1A1 was
determined in dermal ﬁbroblasts.
The most abundant MMP in all three types of ﬁbrob-
lasts is MMP2 followed by MMP14. As shown in Table 1Biochemistry Research International 5
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Figure 2: Proliferation, collagen expression, and basal MMP expression of cardiac, dermal, and pulmonary ﬁbroblasts. (a) Growth
curves were determined in complete growth medium for ﬁbroblasts derived from heart, skin, and lung. Cardiac ﬁbroblasts reveal a lower
proliferation rate compared to dermal and pulmonary ﬁbroblasts. (b) Collagen mRNA expression level was determined using TaqMan from
ﬁbroblasts incubated with or without 10ng/mL TNF-α for 24 hours. Untreated dermal ﬁbroblasts show a signiﬁcantly higher expression
level of collagen (§§§) compared to untreated cardiac and pulmonary ﬁbroblasts, whereas only in dermal and pulmonary ﬁbroblasts TNF-α
treatmentresultedinsigniﬁcantlydecreasedcollagenexpressioncomparedtountreatedcontrols(∗∗∗).(c)Basalexpressionlevelsofdiﬀerent
MMPs in dermal and pulmonary ﬁbroblasts were compared to their expression in cardiac ﬁbroblasts. The most obvious diﬀerence is shown
for MMP1 and MMP3. All mRNA expression levels are shown as absolute expression using the formula 2−ΔCt.
the absolute mRNA expression level of MMP2 does not
diﬀer signiﬁcantly between cardiac, dermal, and pulmonary
ﬁbroblasts, whereas the membrane-bound MMP14 (MT1-
MMP) is signiﬁcantly 2.8-fold lower expressed in dermal
ﬁbroblasts compared to cardiac ﬁbroblasts.
In all three ﬁbroblast types MMP1 is the most expressed
interstitial collagenase whereas the expression in cardiac
ﬁbroblasts is signiﬁcantly 24-fold and 17-fold higher as in
dermal or in pulmonary ﬁbroblasts, respectively. The rarely
expressed collagenase MMP8 is signiﬁcantly 63-fold and6 Biochemistry Research International
54-fold higher expressed in cardiac ﬁbroblasts as well com-
pared to ﬁbroblasts derived from skin or lung, respectively.
The collagenase MMP13 could not be detected in all three
types of ﬁbroblasts (data not shown).
We further investigated the stromelysins MMP3 and
MMP7. Both MMPs are quite low expressed in car-
diac ﬁbroblasts, whereas MMP3 is more expressed than
MMP7 in all three ﬁbroblast types. When compared to
the expression level in cardiac ﬁbroblasts MMP3 is sig-
nificantly 7.0-fold higher expressed in dermal ﬁbroblasts,
whereas it is 8.9-fold lower expressed in pulmonary ﬁ-
broblasts but in this case it did not reach a signiﬁcant
level (P value > 0.05). The stromelysin MMP7 is signif-
icantly 2.0-fold and 9.2-fold lower expressed in dermal
and pulmonary ﬁbroblasts regarding cardiac ﬁbroblasts,
respectively.
The gelatinase MMP9 is one of the lower expressed
MMPsinﬁbroblasts.IndermalﬁbroblaststhemRNAexpres-
sion level is 2.7-fold higher and in pulmonary ﬁbroblasts
1.9-fold lower concerning the mRNA expression in cardiac
ﬁbroblasts.
3.4. Expression of Collagen and Matrix Metalloproteases in
Cardiac, Dermal, and Pulmonary Fibroblasts after TNF-α
Treatment. To explore the inﬂuence of TNF-α treatment
on the expression of collagen we incubated ﬁbroblasts with
10ng/mL TNF-α for 24 hours. After extracting the total
RNA and transcribing that into cDNA TaqMan analysis was
performed. In Figure 2(b) the impact of TNF-α on collagen
expression is presented. Whereas TNF-α treatment resulted
in a 2-fold decreased expression of collagen in ﬁbroblasts
derived from skin or lung, there was no inﬂuence detectable
in cardiac ﬁbroblasts.
Concerning the mRNA expression of MMPs TNF-α
treatment induced an increased expression of all investigated
MMPs in general, whereas the impact of TNF-α on the
expression of the gelatinase MMP2 and membrane-bound
MMP14 (MT1-MMP) did not even reach 2.0-fold increase
(Table 2).
In more detail, MMP1 expression was increased 2.0-fold,
100-fold, and 6.0-fold in cardiac, dermal, and pulmonary
ﬁbroblasts, respectively (Table 2). In Figure 3(a) it is clearly
shown that the TNF-α treatment ﬁnally leads to a similar
mRNA expression of MMP1 in cardiac and dermal ﬁbrob-
lasts, whereas MMP1 is still signiﬁcantly lower expressed
after TNF-α treatment in pulmonary ﬁbroblasts compared
to the cardiac expression levels. Concerning the TNF-α-
inducedchangeinexpressionlevelsofthecollagenaseMMP8
similar results could be observed. TNF-α leads to an increase
of 5.7-fold and 130-fold in cardiac and dermal ﬁbrob-
lasts, respectively, resulting ﬁnally in comparable expression
levels of MMP8 in cardiac and dermal ﬁbroblasts which
demonstrate that no signiﬁcant diﬀerence could be observed
after TNF-α treatment in contrast to the properties prior
to stimulation. In pulmonary ﬁbroblasts the expression of
MMP8 was increased by a factor of 10, but still signiﬁcantly
lower than in cardiac ﬁbroblasts.
In cardiac ﬁbroblasts the stromelysin MMP3 expres-
sion was 6.7-fold increased by TNF-α,w h e r e a si nd e r -
mal and pulmonary ﬁbroblasts an extended increase of
mRNA expression with 9.8-fold and 16-fold was observed,
respectively. However, the resulted MMP3 expression did
not diﬀer between ﬁbroblasts derived from heart or lung
(Figure 3(b)). In contrast TNF-α leads with 3.3-fold and
3.1-fold to a slight increase of MMP7 mRNA expression in
dermal and pulmonary ﬁbroblasts, respectively. However, in
cardiac ﬁbroblasts MMP7 is 16-fold higher expression after
TNF-α treatment.
Interestingly, a high impact of TNF-α on MMP9 expres-
sion was observed in dermal and pulmonary ﬁbroblasts
(127-fold and 90-fold) whereas in cardiac ﬁbroblasts the
resulted change of mRNA expression level was relatively low
with an increase of 7.5-fold. Furthermore, to examine the
MMP9 secretion zymography was used to determine the
protein content of MMP9 in the cell culture supernatants of
cardiac,dermalandpulmonaryﬁbroblasts.Inthecellculture
supernatant of cardiac ﬁbroblasts no MMP9 was detected.
In contrast, dermal, and pulmonary ﬁbroblasts secreted low
amounts of MMP9 which were signiﬁcantly increased by
TNF-α treatment (Figure 3(c)).
4. Discussion
In this study we investigated human primary ﬁbroblasts
derived from diﬀerent types of tissue. We examined the
proliferationrate,theexpressionofcollagen,andthecollagen
degrading MMPs of quiescent ﬁbroblasts and compared
this basal expression pattern between the diﬀerent types
of ﬁbroblasts. Furthermore, we determined the changes of
mRNA expression in these investigated types of ﬁbroblasts
after stimulation with the proinﬂammatory cytokine TNF-α
to determine diﬀerences between ﬁbroblasts isolated from
heart,skin,andlungtissues.Interestingly,thesethreetypesof
ﬁbroblasts reveal major diﬀerences in proliferation rate and
MMP expression.
Regardingotherstudiesfocusedonﬁbroblastsexpression
we suggested that heterogeneities can be identiﬁed [14–17].
It has been reported that even within the single tissue skin
ﬁbroblastsoccurwithdiﬀerentpropertiesconcerningthesite
of origin since dermal ﬁbroblasts from diﬀerent anatomical
sitesshowsimilarmorphologybuttheirowngeneexpression
proﬁle [17]. Here we focused on the expression pattern of
the ECM degradation system which includes the MMPs and
compared this between ﬁbroblasts derived from diﬀerent
organs.
First, we characterized these outgrowth cells using ﬂu-
orescence microscopy. The cultured cells from heart, skin,
and lung tissue showed similar morphology. They appear
as elongated spindle-shaped cells and revealed positive
staining for vimentin and P4HB. To exclude contaminations
with other cells than the expected ﬁbroblasts, for instance,
endothelial cells or muscle cells such as cardiomyocytes from
the heart [18], we stained the cultured cells further with the
muscle marker desmin and the endothelial marker CD31.
Since nearly no positive cells were obtained by this stainingBiochemistry Research International 7
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Figure 3: Alteration of MMP expression levels in cardiac, dermal, and pulmonary ﬁbroblasts after treatment with 10ng/mL TNF-α for 24
hours. Diﬀerent alteration of collagenases (a), stromelysins (b), and MMP9 (c) expression levels after TNF-α treatment. MMP9 activity was
further determined in the cell culture supernatant of cardiac, dermal, and pulmonary ﬁbroblasts. Representative bands of MMP9 activity in
dermal and pulmonary cell culture supernatants with or without TNF-α for 72 hours are shown. No MMP9 activity could be detected in cell
culture supernatant of cardiac ﬁbroblasts. All mRNA expression levels are shown as absolute expression using the formula 2−ΔCt.
we conclude that the presumable ﬁbroblast cultures from
heart, skin, and lung contain almost exclusively primary
ﬁbroblasts.
The ﬁbroblast cell type itself is already known as a pro-
liferating cell [3, 19, 20]. Moreover, we compared the growth
rate of these ﬁbroblasts according to their site of origin. We
clearly demonstrated that ﬁbroblasts derived from skin or
lung revealed a much higher proliferation rate compared to
cardiac ﬁbroblasts. According to the function of the organ
from which the ﬁbroblasts are derived the found diﬀerences8 Biochemistry Research International
are explainable. Skin is the largest organ of the body and
plays crucial role in protecting against external injuries. Skin
wound can arise from environmental inﬂuences such as
mechanical exposures, surgical procedures, or burns. Most
skin wounds can heal naturally due to the existence of highly
proliferating cells which could be a satisfying explanation for
the determined high growth rate of dermal ﬁbroblasts. An
equal proliferation was observed for pulmonary ﬁbroblasts.
Again environmental inﬂuences are able to reach lung tissue
easily by the airway. Therefore, the ability to renew lung
tissue is essential as well [10].
In contrast to skin and lung, for cardiac ﬁbroblasts a
4-fold higher doubling time was determined. The heart
is not directly open for environmental inﬂuences but is
situated within the body and only exposed to the closed
system the blood circulation. Therefore, outside inﬂuences
such as bacteria or virus cannot easily reach the heart
without passing blood vessels. However, further injuries
such as myocardial infarction can occur without direct
contact to the environment. But the probability for such
injuries of the heart is much lower than for injuries of
skin or lung surface. Even if the ﬁbroblast is the most
numerouscelltypeintheheart,cardiomyocytesoccupytwo-
thirds of the tissue volume [7–9]. In contrast to ﬁbroblasts
these cells are not able to proliferate after birth [21].
Consequently after myocardial infarction cardiomyocyte
death occur, followed by migration and proliferation of
ﬁbroblasts and changes in synthesis and degradation of ECM
[3].
Since ﬁbroblasts are the common producers of ECM
consisting mainly of collagen, we determined the mRNA
expressionlevelofthequiescentdermal,pulmonary,andcar-
diac ﬁbroblasts. Cardiac and pulmonary ﬁbroblasts exhibit
an equal expression level of collagen type I in contrast
to dermal ﬁbroblasts revealing a 2-fold higher expression.
We further investigated the collagen expression of the
ﬁbroblast types after TNF-α treatment. TNF-α is one of the
most prominent proinﬂammatory cytokines which is highly
released in response to a large number of inﬂammatory
stimuli, such as LPS or virus antigens [22]. In kidney
mesangial cell cultures treated with TNF-α, alone a mild but
inconsistent reduction in baseline collagen type I level has
been detected [23]. Furthermore, TNF-α was a consistent
and potent inhibitor of the collagen augmentation stimu-
lated by the proﬁbrotic growth factor TGF-β.I th a sb e e n
reported that TNF-α exerted a suppressive eﬀect on Smad3/4
DNA-binding activity [24] being a potential explanation for
the often described antiﬁbrotic eﬀect of TNF-α [23–29]. In
agreement with these data we found signiﬁcantly reduced
collagen mRNA levels after TNF-α treatment in ﬁbroblasts
derived from skin and lung but no inﬂuence of TNF-α on
the collagen expression was observed in cardiac ﬁbroblasts.
Next, we focused on the expression of the proteolytic
ECM degradation system in quiescent dermal, pulmonary,
and cardiac ﬁbroblasts. The MMPs can exist as either soluble
or membrane-type MMPs. Soluble MMPs are synthesized
in a latent form called pro-MMP. These inactive proen-
zymes are secreted into the extracellular space where they
bind to speciﬁc ECM protein and remain quiescent until
the prodomain is cleaved oﬀ [5]. It is known that this
cleaving can be performed by other MMPs [4]. Conversely,
the MT-MMPs incorporate a transmembrane region and
are inserted into the cell membranes in a fully active
state. The family of these enzymes includes a number of
members with various and partly overlapping speciﬁcities
[2, 5]. Therefore, the MMP family is divided into three
groups: collagenases (MMP1, MMP8, and MMP13) which
predominantly degrade interstitial collagen type I, II, and
III, gelatinases (MMP2 and MMP9) degrading gelatins and
b a s e m e n t sm e m b r a n ec o l l a g e ns u c ha sc o l l a g e nI Va sw e l la s
stromelysins(MMP3andMMP7)whichdigestabroadrange
of substrates such as collagen IV, proteoglycans, laminin,
gelatins, and ﬁbronectin [2, 4, 5].
MMP1 is the most expressed soluble collagenase in all
three types of ﬁbroblasts, whereas its expression was about
20-fold higher in cardiac ﬁbroblasts compared to dermal and
pulmonary ﬁbroblasts. MMP8 is very low expressed but also
most expressed in the cardiac ﬁbroblasts. MMP13 could not
be detected in all three human types of ﬁbroblasts, whereas
this collagenase has been referred to as rodent collagenase,
since this is the primary collagenase found in rodents [4].
Another obvious diﬀerence in the basal expression pat-
tern of MMPs was found for the stromelysin MMP3 which
is most expressed in dermal ﬁbroblasts. It has been reported
from fetal skin in comparison to fetal lung ﬁbroblasts that
the net-like collagen type IV is relatively high expressed in
skin [17]. Since MMP3 is able to digest collagen type IV its
higher abundance in skin could be expected.
MMPs catalyze the degradation of ECM macromolecules
such as the interstitial and basement membrane collagens
and therefore facilitate cell migration of inﬂammatory cells
into the injured tissue. The invading inﬂammatory cells
secrete the proinﬂammatory cytokine TNF-α.T h u sw e
further examined the consequences for MMP expression of
ﬁbroblastsafterTNF-αtreatment.Ithasrecentlybeenshown
that the proinﬂammatory cytokine TNF-α is one transcrip-
tional activator for MMP9 in dermal human ﬁbroblasts [30].
Collagen type I is the most expressed collagen in the
heart. Further collagen I and V are strongly expressed in fetal
skin but not in fetal lung ﬁbroblasts [17]. It has already been
reported that TNF-α induced MMP1 mRNA and protein
expression in dermal, gingival, and synovial ﬁbroblasts [31].
In our experiments the TNF-α treatment also revealed an
extreme increase of the collagenase MMP1 in ﬁbroblasts
derived from skin which then reach the equal expression
level as determined in cardiac ﬁbroblasts. In almost the
same manner in dermal ﬁbroblasts MMP8 was as well
increased to a similar level compared to cardiac ﬁbroblasts
after TNF-α treatment. Finally both soluble collagenases
are signiﬁcantly lower expressed in quiescent dermal and
pulmonaryﬁbroblastsbutTNF-αtreatmentleadstoanequal
level of MMP1 and MMP8 as described for cardiac ﬁbroblast
in dermal but not in pulmonary ﬁbroblasts.
The expression of the stromelysins MMP3 and MMP7 is
as well diﬀerentially regulated by TNF-α. Whereas MMP3 is
most expressed in dermal ﬁbroblasts the expression between
cardiac and pulmonary ﬁbroblasts did not diﬀer signiﬁcantly
with or without TNF-α treatment. In contrast MMP7 isBiochemistry Research International 9
most expressed and highly up-regulated by TNF-α in cardiac
ﬁbroblasts compared to ﬁbroblasts from skin or lung.
Furthermore, an extreme upregulation of the gelatinase
MMP9 was determined in dermal and pulmonary ﬁbroblasts
compared to a weak upregulation in cardiac ﬁbroblasts. This
diﬀerence leads to detectable secreted MMP9 protein using
zymography in dermal and pulmonary ﬁbroblasts but not in
cardiacﬁbroblasts.OnesubstrateofMMP9iscollagenIV,the
net-like collagen which forms the basement membrane, and
therefore MMP9 facilitates cell migration into the injured
tissue.
As already mentioned, the activity of MMPs is regulated
through transcriptional activators such as TNF-α. Further-
morethepresenceofactiveMMPsisalsoregulatedbycontrol
of posttranslational cleaving and the presence of endogenous
inhibitorsso-calledtissueinhibitorofMMPs(TIMPs).These
TIMPs bind noncovalently to the catalytic domain of MMPs
in a 1:1 stoichiometry and therefore prevent the access of
the substrate to the active site of the enzyme [32]. Proteolysis
becomes pathological, when the normal balance between
MMPs and their inhibitors TIMPs is lost. In this study
we focused on the transcriptional regulation but several
studies have been performed to get a better understanding
forthe posttranslational control. Forinstance in the presence
of MMP3 a 12-fold increase, in the conversion of pro-
MMP1 to active MMP1 was reported [33]. In other studies,
inﬂammatory cytokines such as IL-1α are known to play
a major role in regulating MMP and TIMP expression in
several inﬂammatory diseases. The stimulatory eﬀect of IL-
1αaswellasTNF-αhasbeenreportedforboththeexpression
ofMMPsandTIMPsindentalpulpﬁbroblastswhichleadsto
an alteration of the balance between the MMPs and TIMPs
[34, 35].
Beyond their eﬀects on matrix degradation to facilitate
the invasion of inﬂammatory cells, MMPs can further
modulate inﬂammatory pathways by processing cytokines,
chemokines, and growth factors. For example, MMP7 and
the membrane-bound MMP14 have both been identiﬁed to
process membrane-bound TNF-α to a soluble active TNF-
α form enhancing its biological activity [36]. On the other
hand MMPs can cleave chemokines which are responsible
for recruiting more inﬂammatory cells to the site of injury.
Chemokine cleavage by MMPs most often results in reduced
chemokine activity [37–39]. It has been especially shown
for CC-chemokines that MMP cleavage creates chemokine
receptor antagonists and thus MMPs damp inﬂammation
and are strongly involved in a kind of negative feedback
mechanism to prevent too extensive inﬂammation [39]
(Westermann et al. 2011, accepted) [40].
In the past the ﬁbroblasts have typically been understood
as a uniform cell population with comparable function
regardless of their origin. Here we demonstrated serious
diﬀerences in proliferation, collagen synthesis as well as
MMP expression under basal or inﬂammatory conditions.
However, an excess of MMPs resulting in degradation of
ECM is thought to be a key feature of the pathology of
various inﬂammatory and degenerative diseases [41–43].
Since extensive heterogeneity among ﬁbroblasts from diﬀer-
ent tissues has been demonstrated, it is essential to examine
cardiac ﬁbroblasts to understand myocardial dysfunctions
even if it is more diﬃcult to obtain and to cultivate cardiac
ﬁbroblasts.
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